Department of Breast Surgery, Cancer Center/Cancer Institute, Fudan University, 399 Ling-Ling Road, Shanghai 200032, People's Republic of China.
Breast Cancer Res Treat. 2012 Jan;131(1):27-31. doi: 10.1007/s10549-010-1133-3. Epub 2010 Aug 25.
The association between single-nucleotide polymorphisms (SNPs) in the interleukin-10 (IL-10) gene promoter and breast cancer risk is still ambiguous. We here performed a meta-analysis based on the evidence currently available from the literature to make a more precise estimation of the relationship between two genetic variants in the IL-10 gene promoter, -1082A > G (rs1800896) and -592C > A (rs1800872), and breast cancer. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the corresponding strengths of association under the codominant, dominant, and recessive models. A total of ten studies (4,181 cases and 4,384 controls) were eligible for meta-analysis. There were six studies with 3,032 cases and 3,190 controls for rs1800872, and eight studies with 1,636 cases and 1,670 controls for rs1800896. Meta-analysis showed that neither of the two polymorphisms had any association with increased breast cancer risk (for rs1800896: OR = 1.060, 95% CI = 0.785-1.432 in the dominant model, and OR = 1.152, 95% CI = 0.958-1.386 in the recessive model; and for rs1800872: OR = 0.952, 95% CI = 0.859-1.056 in the dominant model, and OR = 0.892, 95% CI = 0.741-1.072 in the recessive model). The results did not change when the analyses were restricted in Caucasians, or in the studies fulfilling Hardy-Weinberg equilibrium, or according to source of controls. In outlier analysis, no individual study affected the overall OR dominantly, since omission of any single study made no material huge difference. In conclusion, the present meta-analysis suggests a lack of association between the two SNPs (rs1800896 and rs1800872) in the IL-10 gene promoter and breast cancer risk. Further studies, either with larger sample size or regarding other SNPs/haplotypes within the IL-10 gene, are needed to clarify the role of IL-10 in breast carcinogenesis.
白细胞介素-10（IL-10）基因启动子中单核苷酸多态性（SNP）与乳腺癌风险之间的关联仍不明确。我们在此进行了一项荟萃分析，根据目前文献中的证据，更精确地评估了 IL-10 基因启动子中两个遗传变异体-1082A > G（rs1800896）和-592C > A（rs1800872）与乳腺癌之间的关系。在共显性、显性和隐性模型下，使用优势比（OR）和 95%置信区间（CI）来评估相应的关联强度。共有 10 项研究（4181 例病例和 4384 例对照）符合荟萃分析的条件。其中 6 项研究（3032 例病例和 3190 例对照）针对 rs1800872，8 项研究（1636 例病例和 1670 例对照）针对 rs1800896。荟萃分析显示，这两种多态性均与乳腺癌风险增加无关（对于 rs1800896：显性模型中的 OR = 1.060，95%CI = 0.785-1.432，隐性模型中的 OR = 1.152，95%CI = 0.958-1.386；对于 rs1800872：显性模型中的 OR = 0.952，95%CI = 0.859-1.056，隐性模型中的 OR = 0.892，95%CI = 0.741-1.072）。当分析仅限于白种人、符合 Hardy-Weinberg 平衡的研究或根据对照来源进行时，结果没有改变。在异常值分析中，没有单个研究占主导地位地影响总体 OR，因为排除任何单个研究都没有产生实质性的巨大差异。总之，本荟萃分析表明，IL-10 基因启动子中的两个 SNP（rs1800896 和 rs1800872）与乳腺癌风险之间没有关联。需要进一步的研究，无论是样本量更大的研究，还是关于 IL-10 基因内其他 SNP/单倍型的研究，都需要阐明 IL-10 在乳腺癌发生中的作用。
